{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:39:43Z","timestamp":1792784383020,"version":"4.5.0"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Welcome Trust","award":["200181\/Z\/15\/Z"],"award-info":[{"award-number":["200181\/Z\/15\/Z"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Neuroscience"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.mcn.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T04:08:10Z","timestamp":1551067690000},"page":"67-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Fluid and imaging biomarkers for Huntington's disease"],"prefix":"10.1016","volume":"97","author":[{"given":"Paul","family":"Zeun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael I.","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-7887","authenticated-orcid":false,"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcn.2019.02.004_bb0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.nicl.2017.07.011","article-title":"Diffusion tensor imaging in Parkinson's disease: review and meta-analysis","volume":"16","author":"Atkinson-Clement","year":"2017","journal-title":"NeuroImage: Clinical"},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1212\/WNL.50.1.252","article-title":"Frontal lobe volume in patients with Huntington's disease","volume":"50","author":"Aylward","year":"1998","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2010.208264","article-title":"Longitudinal change in regional brain volumes in prodromal Huntington disease","volume":"82","author":"Aylward","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0020","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.biopsych.2011.07.030","article-title":"Striatal volume contributes to the prediction of onset of Huntington disease in incident cases","volume":"71","author":"Aylward","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0025","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JHD-130076","article-title":"Regional atrophy associated with cognitive and motor function in prodromal Huntington disease","volume":"2","author":"Aylward","year":"2013","journal-title":"J. Huntingtons Dis."},{"issue":"12","key":"10.1016\/j.mcn.2019.02.004_bb0030","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00415-009-5196-1","article-title":"Delayed onset of the diurnal melatonin rise in patients with Huntington's disease","volume":"256","author":"Aziz","year":"2009","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14789450.2017.1304217","article-title":"Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases","volume":"14","author":"Baldacci","year":"2017","journal-title":"Expert Rev. Proteomics"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000096887","article-title":"Permeability of the blood-brain barrier to soluble cytokine receptors","volume":"2","author":"Banks","year":"1995","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.mcn.2019.02.004_bb0045","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0050","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J. Neurochem."},{"issue":"32","key":"10.1016\/j.mcn.2019.02.004_bb0055","doi-asserted-by":"crossref","first-page":"19633","DOI":"10.1074\/jbc.272.32.19633","article-title":"Oxidative decay of DNA","volume":"272","author":"Beckman","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.mcn.2019.02.004_bb0060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.wnn.0000152205.79033.73","article-title":"White matter volume and cognitive dysfunction in early Huntington's disease","volume":"18","author":"Beglinger","year":"2005","journal-title":"Cogn. Behav. Neurol."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/JHD-2012-120007","article-title":"Plasma 8-hydroxy-2\u2032-deoxyguanosine levels in Huntington disease and healthy controls treated with coenzyme Q10","volume":"1","author":"Biglan","year":"2012","journal-title":"Journal of Huntington's Disease"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0075","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1399-0004.2006.00636.x","article-title":"Cerebrospinal fluid levels of orexin-a are not a clinically useful biomarker for Huntington disease","volume":"70","author":"Bjorkqvist","year":"2006","journal-title":"Clin. Genet."},{"issue":"13","key":"10.1016\/j.mcn.2019.02.004_bb0080","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1002\/mds.21447","article-title":"Cocaine- and amphetamine-regulated transcript is increased in Huntington disease","volume":"22","author":"Bjorkqvist","year":"2007","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.mcn.2019.02.004_bb0085","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuron.2009.09.034","article-title":"Harnessing immune alterations in neurodegenerative diseases","volume":"64","author":"Bj\u00f6rkqvist","year":"2009","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.nbd.2011.02.010","article-title":"Connectivity-based segmentation of the striatum in Huntington's disease: vulnerability of motor pathways","volume":"42","author":"Bohanna","year":"2011","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0100","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","article-title":"Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation","volume":"22","author":"Bonneh-Barkay","year":"2012","journal-title":"Brain Pathol."},{"issue":"21","key":"10.1016\/j.mcn.2019.02.004_bb0105","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1212\/WNL.0b013e318293e1a1","article-title":"8OHdG is not a biomarker for Huntington disease state or progression","volume":"80","author":"Borowsky","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JHD-160213","article-title":"Plasma cytokine levels in relation to neuropsychiatric symptoms and cognitive dysfunction in Huntington's disease","volume":"5","author":"Bouwens","year":"2016","journal-title":"J. Huntingtons Dis."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","article-title":"Oxidative stress in Huntington's disease","volume":"9","author":"Browne","year":"1999","journal-title":"Brain Pathol."},{"issue":"8","key":"10.1016\/j.mcn.2019.02.004_bb0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"issue":"458","key":"10.1016\/j.mcn.2019.02.004_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.mcn.2019.02.004_bb0130","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","article-title":"The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease","volume":"21","author":"Campesan","year":"2011","journal-title":"Curr. Biol."},{"key":"10.1016\/j.mcn.2019.02.004_bb0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington's disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.mcn.2019.02.004_bb0140","doi-asserted-by":"crossref","unstructured":"Ciammola, A., J. Sassone, M. Cannella, S. Calza, B. Poletti, L. Frati, F. Squitieri and V. Silani (2007). \"Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients.\" Am J Med Genet B Neuropsychiatr Genet 144b(4): 574\u2013577.","DOI":"10.1002\/ajmg.b.30501"},{"key":"10.1016\/j.mcn.2019.02.004_bb0145","unstructured":"clinicaltrials.gov NCT02507284 (2018) \"Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease.\" Retrieved 20th January 2019, from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02507284."},{"key":"10.1016\/j.mcn.2019.02.004_bb0150","unstructured":"clinicaltrials.gov NCT02519036. (2015). \"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in PatientsWith Early Manifest Huntington's Disease.\" Retrieved 12th August 2018, from https:\/\/ClinicalTrials.gov\/show\/NCT02519036."},{"key":"10.1016\/j.mcn.2019.02.004_bb0155","unstructured":"clinicaltrials.gov NCT03225846 (2018). \"Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease (PRECISION-HD2).\" Retrieved 21st August 2018, from https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03225846."},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0160","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.parkreldis.2008.05.012","article-title":"Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease","volume":"15","author":"Constantinescu","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0165","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.parkreldis.2011.06.010","article-title":"Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease","volume":"17","author":"Constantinescu","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0170","first-page":"219","article-title":"Behavioral changes in Huntington disease","volume":"14","author":"Craufurd","year":"2001","journal-title":"Neuropsychiatry Neuropsychol. Behav. Neurol."},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0175","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3233\/JHD-130077","article-title":"Corpus callosal atrophy in premanifest and early Huntington's disease","volume":"2","author":"Crawford","year":"2013","journal-title":"J. Huntingtons Dis."},{"issue":"7","key":"10.1016\/j.mcn.2019.02.004_bb0180","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J. Proteome Res."},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0185","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3174\/ajnr.A2128","article-title":"Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study","volume":"31","author":"Della Nave","year":"2010","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0190","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/hbm.22055","article-title":"The structural correlates of functional deficits in early huntington's disease","volume":"34","author":"Delmaire","year":"2013","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.mcn.2019.02.004_bb0195","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuropharm.2017.01.016","article-title":"In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects","volume":"117","author":"Delnomdedieu","year":"2017","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.mcn.2019.02.004_bb0200","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/jnnp.46.12.1134","article-title":"Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease","volume":"46","author":"Durso","year":"1983","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.mcn.2019.02.004_bb0205","doi-asserted-by":"crossref","first-page":"541259","DOI":"10.1155\/2013\/541259","article-title":"The role of the immune system in Huntington's disease","volume":"2013","author":"Ellrichmann","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.mcn.2019.02.004_bb0210","series-title":"Guideline on Bioanalytical Method Validation","author":"European Medicines Agency","year":"2011"},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0215","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3171\/2013.2.JNS121294","article-title":"White matter fiber tractography: why we need to move beyond DTI","volume":"118","author":"Farquharson","year":"2013","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.mcn.2019.02.004_bb0220","series-title":"BEST Biomarkers, EndpointS, and Other Tools","author":"FDA, N","year":"2016"},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0225","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JHD-170269","article-title":"Validation of ultrasensitive mutant huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay","volume":"6","author":"Fodale","year":"2017","journal-title":"Journal of Huntington's Disease"},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0230","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","article-title":"Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease","volume":"112","author":"Forrest","year":"2010","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0235","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00401-010-0742-6","article-title":"Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses","volume":"120","author":"Gabery","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"12","key":"10.1016\/j.mcn.2019.02.004_bb0240","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/sleep\/28.12.1607","article-title":"CSF hypocretin levels are normal in Huntington's disease patients","volume":"28","author":"Gaus","year":"2005","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0245","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.neubiorev.2013.01.022","article-title":"Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials","volume":"37","author":"Georgiou-Karistianis","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0250","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng1542","article-title":"A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease","volume":"37","author":"Giorgini","year":"2005","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0255","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3233\/JHD-150173","article-title":"Longitudinal diffusion tensor imaging shows progressive changes in white matter in Huntington's disease","volume":"4","author":"Gregory","year":"2015","journal-title":"J. Huntingtons Dis."},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0260","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-3940(00)00956-3","article-title":"Early kynurenergic impairment in Huntington's disease and in a transgenic animal model","volume":"283","author":"Guidetti","year":"2000","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.mcn.2019.02.004_bb0265","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1006\/exnr.1998.6919","article-title":"Regional specificity of brain atrophy in Huntington's disease","volume":"154","author":"Halliday","year":"1998","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/brb3.185","article-title":"Neuroanatomical correlates of cognitive functioning in prodromal Huntington disease","volume":"4","author":"Harrington","year":"2014","journal-title":"Brain Behav."},{"issue":"11","key":"10.1016\/j.mcn.2019.02.004_bb0275","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/mds.26803","article-title":"Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease","volume":"31","author":"Harrington","year":"2016","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ana.410310113","article-title":"Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease","volume":"31","author":"Harris","year":"1992","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0285","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/01.wnl.0000230149.36635.c8","article-title":"Increased rate of whole-brain atrophy over 6 months in early Huntington disease","volume":"67","author":"Henley","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mcn.2019.02.004_bb0290","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0295","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.mcn.2019.02.004_bb0300","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0304-3940(91)90874-S","article-title":"Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease","volume":"122","author":"Heyes","year":"1991","journal-title":"Neurosci. Lett."},{"issue":"Pt 5","key":"10.1016\/j.mcn.2019.02.004_bb0305","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0310","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3174\/ajnr.A2018","article-title":"Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study","volume":"31","author":"Hobbs","year":"2010","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0315","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/mds.23747","article-title":"The structural involvement of the cingulate cortex in premanifest and early Huntington's disease","volume":"26","author":"Hobbs","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcn.2019.02.004_bb0320","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.nicl.2012.12.001","article-title":"Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: baseline results from the PADDINGTON study","volume":"2","author":"Hobbs","year":"2013","journal-title":"NeuroImage: Clinical"},{"issue":"12","key":"10.1016\/j.mcn.2019.02.004_bb0325","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1136\/jnnp-2014-309768","article-title":"Short-interval observational data to inform clinical trial design in Huntington's disease","volume":"86","author":"Hobbs","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.mcn.2019.02.004_bb0330","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.nicl.2018.03.013","article-title":"Resting-state connectivity in neurodegenerative disorders: is there potential for an imaging biomarker?","volume":"18","author":"Hohenfeld","year":"2018","journal-title":"NeuroImage: Clinical"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0335","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jne.12255","article-title":"Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease and its association with depressive symptoms and suicidality","volume":"27","author":"Hubers","year":"2015","journal-title":"J. Neuroendocrinol."},{"issue":"2","key":"10.1016\/j.mcn.2019.02.004_bb0340","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: reliability and consistency. Huntington study group","volume":"11","author":"Huntington Study Group","year":"1996","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0345","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","article-title":"Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases","volume":"130","author":"Jauch","year":"1995","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.mcn.2019.02.004_bb0350","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/mds.21620","article-title":"Variation of selective gray and white matter atrophy in Huntington's disease","volume":"22","author":"Jech","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcn.2019.02.004_bb0355","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3389\/fneur.2017.00519","article-title":"Recommendations for the use of automated gray matter segmentation tools: evidence from Huntington's disease","volume":"8","author":"Johnson","year":"2017","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.mcn.2019.02.004_bb0360","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.1212\/WNL.0000000000005005","article-title":"Neurofilament light protein in blood predicts regional atrophy in Huntington disease","volume":"90","author":"Johnson","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0365","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbadis.2011.11.014","article-title":"Antioxidants in Huntington's disease","volume":"1822","author":"Johri","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mcn.2019.02.004_bb0370","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2013.04.016","article-title":"PGC-1alpha, mitochondrial dysfunction, and Huntington's disease","volume":"62","author":"Johri","year":"2013","journal-title":"Free Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.mcn.2019.02.004_bb0375","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00415-008-0050-4","article-title":"Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease","volume":"255","author":"Jurgens","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.mcn.2019.02.004_bb0380","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.neuroimage.2016.06.002","article-title":"Multi-compartment microscopic diffusion imaging","volume":"139","author":"Kaden","year":"2016","journal-title":"Neuroimage"},{"issue":"12","key":"10.1016\/j.mcn.2019.02.004_bb0385","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/mds.26003","article-title":"Plasma melatonin is reduced in Huntington's disease","volume":"29","author":"Kalliolia","year":"2014","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.mcn.2019.02.004_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138848","article-title":"A 24-hour study of the hypothalamo-pituitary axes in Huntington's disease","volume":"10","author":"Kalliolia","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0395","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/cercor\/bhh185","article-title":"Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis","volume":"15","author":"Kassubek","year":"2005","journal-title":"Cereb. Cortex"},{"issue":"10","key":"10.1016\/j.mcn.2019.02.004_bb0400","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0405","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/jnnp.2004.047993","article-title":"Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study","volume":"76","author":"Kipps","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0410","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00005072-199007000-00002","article-title":"Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease","volume":"49","author":"Kremer","year":"1990","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.mcn.2019.02.004_bb0415","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psychres.2012.09.022","article-title":"Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease","volume":"207","author":"Labuschagne","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.mcn.2019.02.004_bb0420","series-title":"Molecular Imaging in Dementia: Past, Present, and Future","author":"Laforce","year":"2018"},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0425","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin. Genet."},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0430","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.24495","article-title":"Sleep deficits but no metabolic deficits in premanifest Huntington's disease","volume":"78","author":"Lazar","year":"2015","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.mcn.2019.02.004_bb0435","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0024-3205(79)90357-6","article-title":"Growth hormone and prolactin secretion in Huntington's disease","volume":"24","author":"Levy","year":"1979","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0440","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0896-6273(93)90127-D","article-title":"Huntington's disease gene (IT15) is widely expressed in human and rat tissues","volume":"11","author":"Li","year":"1993","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0445","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.nbd.2012.02.012","article-title":"8OHdG as a marker for Huntington disease progression","volume":"46","author":"Long","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2019.02.004_bb0450","unstructured":"MacDonald, D., B. Borrowsky, J. Bard, R. Cachope, L. Park, J. Wityak, V. Dilda, Wood A, L. Mrzljak, C. Sampaio, R. Pacifici, E. Singer, I. Munoz-Sanjuan, C. Dominguez and T. Vogt (2015). \"Pharmacodynamic Biomarkers for HTT-Lowering Therapies.\""},{"issue":"14","key":"10.1016\/j.mcn.2019.02.004_bb0455","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/mds.23912","article-title":"Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation","volume":"26","author":"Majid","year":"2011","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.mcn.2019.02.004_bb0460","doi-asserted-by":"crossref","first-page":"a006247","DOI":"10.1101\/cshperspect.a006247","article-title":"Biochemistry and cell biology of tau protein in neurofibrillary degeneration","volume":"2","author":"Mandelkow","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.mcn.2019.02.004_bb0465","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainres.2005.09.028","article-title":"Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease","volume":"1063","author":"Meier","year":"2005","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0470","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.52.5.1104","article-title":"Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease","volume":"52","author":"Montine","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0475","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/1531-8249(200012)48:6<950::AID-ANA23>3.0.CO;2-F","article-title":"No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls","volume":"48","author":"Montine","year":"2000","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0480","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000115147","article-title":"Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson's disease and Huntington's chorea","volume":"19","author":"Murri","year":"1980","journal-title":"Eur. Neurol."},{"issue":"2","key":"10.1016\/j.mcn.2019.02.004_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172762","article-title":"Tau or neurofilament light-which is the more suitable biomarker for Huntington's disease?","volume":"12","author":"Niemela","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mcn.2019.02.004_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193492","article-title":"Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease","volume":"13","author":"Niemel\u00e4","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.mcn.2019.02.004_bb0495","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuroscience.2012.05.043","article-title":"Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease","volume":"251","author":"Nithianantharajah","year":"2013","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0500","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1002\/hbm.22756","article-title":"Microstructural brain abnormalities in Huntington's disease: a two-year follow-up","volume":"36","author":"Odish","year":"2015","journal-title":"Hum. Brain Mapp."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0505","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/mds.25864","article-title":"The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation","volume":"29","author":"Papoutsi","year":"2014","journal-title":"Mov. Disord."},{"issue":"439","key":"10.1016\/j.mcn.2019.02.004_bb0510","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam9100","article-title":"Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates","volume":"10","author":"Parker","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0515","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archneur.63.6.883","article-title":"Preparing for preventive clinical trials: the predict-HD study","volume":"63","author":"Paulsen","year":"2006","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0520","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.biopsych.2005.06.003","article-title":"Brain structure in preclinical Huntington's disease","volume":"59","author":"Paulsen","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.mcn.2019.02.004_bb0525","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington's disease decades before diagnosis: the predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3\u20134","key":"10.1016\/j.mcn.2019.02.004_bb0530","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainresbull.2010.04.003","article-title":"Striatal and white matter predictors of estimated diagnosis for Huntington disease","volume":"82","author":"Paulsen","year":"2010","journal-title":"Brain Res. Bull."},{"issue":"12","key":"10.1016\/j.mcn.2019.02.004_bb0535","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1474-4422(14)70238-8","article-title":"Prediction of manifest Huntington disease with clinical and imaging measures: a 12-year prospective observational study","volume":"13","author":"Paulsen","year":"2014","journal-title":"Lancet Neurol."},{"issue":"1\u20132","key":"10.1016\/j.mcn.2019.02.004_bb0540","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0304-3940(92)90749-W","article-title":"Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease","volume":"144","author":"Pearson","year":"1992","journal-title":"Neurosci. Lett."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0545","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ana.410410521","article-title":"CAG repeat number governs the development rate of pathology in Huntington's disease","volume":"41","author":"Penney","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2019.02.004_bb0550","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.nbd.2014.01.013","article-title":"White matter connectivity reflects clinical and cognitive status in Huntington's disease","volume":"65","author":"Poudel","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.mcn.2019.02.004_bb0555","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbadis.2011.10.016","article-title":"Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease","volume":"1822","author":"Reddy","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0560","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JHD-189001","article-title":"Huntington's disease clinical trials corner: February 2018","volume":"7","author":"Rodrigues","year":"2018","journal-title":"J. Huntingtons Dis."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0565","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.13719","article-title":"Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease","volume":"139","author":"Rodrigues","year":"2016","journal-title":"J. Neurochem."},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163479","article-title":"Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's disease","volume":"11","author":"Rodrigues","year":"2016","journal-title":"PLoS One"},{"issue":"Suppl. 3","key":"10.1016\/j.mcn.2019.02.004_bb0580","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1016\/S1353-8020(08)70035-X","article-title":"Hypocretin-1 and secondary signs in Huntington's disease","volume":"13","author":"Roos","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0585","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.58.5.695","article-title":"Regional and progressive thinning of the cortical ribbon in Huntington's disease","volume":"58","author":"Rosas","year":"2002","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.mcn.2019.02.004_bb0590","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/01.WNL.0000065888.88988.6E","article-title":"Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis","volume":"60","author":"Rosas","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0595","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.20979","article-title":"Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures","volume":"21","author":"Rosas","year":"2006","journal-title":"Mov. Disord."},{"issue":"Pt 4","key":"10.1016\/j.mcn.2019.02.004_bb0600","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","article-title":"Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity","volume":"131","author":"Rosas","year":"2008","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0605","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1016\/j.neuroimage.2009.10.015","article-title":"Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical \"disconnection\"","volume":"49","author":"Rosas","year":"2010","journal-title":"Neuroimage"},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0610","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/mds.23762","article-title":"A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study","volume":"26","author":"Rosas","year":"2011","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0615","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bpa.12426","article-title":"Huntington's disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain","volume":"26","author":"Rub","year":"2016","journal-title":"Brain Pathol."},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004962","article-title":"Neuroendocrine disturbances in Huntington's disease","volume":"4","author":"Saleh","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0625","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","article-title":"Formation of polyglutamine inclusions in non-CNS tissue","volume":"8","author":"Sathasivam","year":"1999","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0630","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17530059.2012.701205","article-title":"Biomarkers for Huntington's disease: an update","volume":"6","author":"Scahill","year":"2012","journal-title":"Expert Opin Med Diagn"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0635","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hbm.21449","article-title":"Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy","volume":"34","author":"Scahill","year":"2013","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.mcn.2019.02.004_bb0640","first-page":"247","article-title":"Chapter 20 - structural imaging in premanifest and manifest Huntington disease. Handbook of clinical neurology. A. S. Feigin and K. E. Anderson","volume":"144","author":"Scahill","year":"2017","journal-title":"Elsevier."},{"issue":"Suppl. 1","key":"10.1016\/j.mcn.2019.02.004_bb0645","article-title":"A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington's disease (hd)","volume":"89","author":"Schobel","year":"2018","journal-title":"Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0650","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hbm.23465","article-title":"Longitudinal diffusion changes in prodromal and early HD: evidence of white-matter tract deterioration","volume":"38","author":"Shaffer","year":"2017","journal-title":"Hum. Brain Mapp."},{"issue":"11","key":"10.1016\/j.mcn.2019.02.004_bb0655","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.psyneuen.2012.10.020","article-title":"Cortisol and depression in pre-diagnosed and early stage Huntington's disease","volume":"38","author":"Shirbin","year":"2013","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0660","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JHD-130049","article-title":"A critical evaluation of inflammatory markers in Huntington's disease plasma","volume":"2","author":"Silajdzic","year":"2013","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.mcn.2019.02.004_bb0665","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neurobiolaging.2017.04.021","article-title":"ApoE influences regional white-matter axonal density loss in Alzheimer's disease","volume":"57","author":"Slattery","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.mcn.2019.02.004_bb0670","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1038\/srep12166","article-title":"Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression","volume":"5","author":"Southwell","year":"2015","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0675","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1017\/S003329171300247X","article-title":"The neuroanatomy of subthreshold depressive symptoms in Huntington's disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study","volume":"44","author":"Sprengelmeyer","year":"2014","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1755-5949.2008.00068.x","article-title":"Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease","volume":"15","author":"Squitieri","year":"2009","journal-title":"CNS Neurosci. Ther."},{"issue":"15","key":"10.1016\/j.mcn.2019.02.004_bb0685","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1212\/WNL.0b013e3181d8c20a","article-title":"Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study","volume":"74","author":"Stoffers","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0020937","article-title":"Neurocognitive signs in prodromal Huntington disease","volume":"25","author":"Stout","year":"2011","journal-title":"Neuropsychology"},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0695","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington's disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0700","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mds.26118","article-title":"A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers","volume":"30","author":"Sturrock","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcn.2019.02.004_bb0705","series-title":"Effects of IONIS-HTTRx in Patients with Early Huntington's Disease: Results of the First HTT-Lowering Drug Trial","author":"Tabrizi","year":"2018"},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0710","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0715","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","article-title":"Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis","volume":"10","author":"Tabrizi","year":"2011","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.mcn.2019.02.004_bb0720","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.mcn.2019.02.004_bb0725","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol."},{"issue":"Pt 8","key":"10.1016\/j.mcn.2019.02.004_bb0730","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/brain\/awf179","article-title":"The distribution of structural neuropathology in pre-clinical Huntington's disease","volume":"125","author":"Thieben","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.mcn.2019.02.004_bb0735","unstructured":"US Department of Health and Human Services, e. a. (2018). Bioanalytical Method Validation Guiance for Industry."},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0740","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00415-010-5768-0","article-title":"Early atrophy of pallidum and accumbens nucleus in Huntington's disease","volume":"258","author":"van den Bogaard","year":"2011","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.mcn.2019.02.004_bb0745","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","article-title":"Beyond the brain: widespread pathology in Huntington's disease","volume":"8","author":"van der Burg","year":"2009","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0750","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1750-3639.2012.00565.x","article-title":"Paraventricular nucleus neuropeptide expression in Huntington's disease patients","volume":"22","author":"van Wamelen","year":"2012","journal-title":"Brain Pathol."},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0755","article-title":"Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease","volume":"3","author":"Vinther-Jensen","year":"2016","journal-title":"Neurol. Neurophysiol. Neurosci."},{"issue":"6","key":"10.1016\/j.mcn.2019.02.004_bb0760","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"Pt 7","key":"10.1016\/j.mcn.2019.02.004_bb0765","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"The role of tau in the pathological process and clinical expression of Huntington's disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0770","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jnc.13624","article-title":"Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's disease: increased NPY levels and differential degradation of the NPY1-30 fragment","volume":"137","author":"Wagner","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2019.02.004_bb0775","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fphys.2014.00231","article-title":"Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients","volume":"5","author":"Wang","year":"2014","journal-title":"Front. Physiol."},{"issue":"11","key":"10.1016\/j.mcn.2019.02.004_bb0780","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","article-title":"Targets for future clinical trials in Huntington's disease: what's in the pipeline?","volume":"29","author":"Wild","year":"2014","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.mcn.2019.02.004_bb0785","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington's disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.mcn.2019.02.004_bb0790","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mcn.2019.02.004_bb0795","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2017.00011","article-title":"Molecular imaging markers to track Huntington's disease pathology","volume":"8","author":"Wilson","year":"2017","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.mcn.2019.02.004_bb0800","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nan.12378","article-title":"Review: tau in biofluids - relation to pathology, imaging and clinical features","volume":"43","author":"Zetterberg","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"9","key":"10.1016\/j.mcn.2019.02.004_bb0805","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archneur.63.9.1277","article-title":"Neurochemical aftermath of amateur boxing","volume":"63","author":"Zetterberg","year":"2006","journal-title":"Arch. Neurol."},{"issue":"Pt 9","key":"10.1016\/j.mcn.2019.02.004_bb0810","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1093\/brain\/awp071","article-title":"White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI","volume":"132","author":"Zhang","year":"2009","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.mcn.2019.02.004_bb0815","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.neuroimage.2012.03.072","article-title":"NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain","volume":"61","author":"Zhang","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.mcn.2019.02.004_bb0820","series-title":"In Vivo Characterization of White Matter Pathology in Pre-Manifest Huntington's Disease","author":"Zhang","year":"2018"},{"issue":"5529","key":"10.1016\/j.mcn.2019.02.004_bb0825","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.mcn.2019.02.004_bb0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022966","article-title":"Brain-derived neurotrophic factor in patients with Huntington's disease","volume":"6","author":"Zuccato","year":"2011","journal-title":"PLoS One"}],"container-title":["Molecular and Cellular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743118303440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743118303440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:08:36Z","timestamp":1760922516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044743118303440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":165,"alternative-id":["S1044743118303440"],"URL":"https:\/\/doi.org\/10.1016\/j.mcn.2019.02.004","relation":{},"ISSN":["1044-7431"],"issn-type":[{"value":"1044-7431","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluid and imaging biomarkers for Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcn.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}